PBAC Public Summary Documents – December 2025

Page last updated: 24 April 2026

Public Summary Documents relating to the December 2025 PBAC meeting.

• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - December 2025

The following Public Summary Documents have been updated:

March 2025 PBAC Meeting

• Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®

May 2025 PBAC Meeting

• Raxtozinameran: I.M. injection, suspension for injection containing raxtozinameran 30 micrograms; Comirnaty® Omicron XBB.1.5

July 2025 PBAC Meeting

• Eplerenone; Tablet 25 mg, Tablet 50 mg; Inspra®
• Seladelpar: Capsule 10 mg; Livdelzi
• Velmanase Alpha; Powder for I.V. infusion 10 mg; Lamzede®Velmanase Alpha; Powder for I.V. infusion 10 mg; Lamzede®